Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(67%)

Phase Distribution

Ph phase_4
1
33%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(2)
Other(1)

Detailed Status

Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (50.0%)
Phase 41 (50.0%)

Trials by Status

terminated267%
unknown133%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_4

Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis

NCT03696290
terminatedphase_2

Nebulized Aztreonam for Prevention of Gram Negative Ventilator-associated Pneumonia

NCT03749226
unknown

Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis

NCT00989807

Clinical Trials (3)

Showing 3 of 3 trials
NCT03696290Phase 4

Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis

Terminated
NCT03749226Phase 2

Nebulized Aztreonam for Prevention of Gram Negative Ventilator-associated Pneumonia

Terminated
NCT00989807

Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3